Macrophage-mediated myelin recycling fuels brain cancer malignancy

Daan J. Kloosterman(The Netherlands Cancer Institute), Johanna Erbani(The Netherlands Cancer Institute), Menno Boon(The Netherlands Cancer Institute), Martina Farber(The Netherlands Cancer Institute), Shanna M. Handgraaf(The Netherlands Cancer Institute), Masami Ando‐Kuri(The Netherlands Cancer Institute), Elena Sánchez‐López(Leiden University Medical Center), Bauke Fontein(The Netherlands Cancer Institute), Marjolijn Mertz(The Netherlands Cancer Institute), Marja Nieuwland(The Netherlands Cancer Institute), Ning Qing Liu(Erasmus MC Cancer Institute), Gabriel Forn‐Cuní(Leiden University), Nicole N. van der Wel, Anita E. Grootemaat, Luuk Reinalda(Leiden University), Sander I. van Kasteren(Leiden University), Elzo de Wit(The Netherlands Cancer Institute), Brian Ruffell(Moffitt Cancer Center), B. Ewa Snaar‐Jagalska(Leiden University), Kevin Petrecca(McGill University Health Centre), Dieta Brandsma(The Netherlands Cancer Institute), Alexander Kros(Leiden University), Martin Giera(Leiden University Medical Center), Leila Akkari(The Netherlands Cancer Institute)
Cell
August 12, 2024
Cited by 177Open Access
Full Text

Abstract

Tumors growing in metabolically challenged environments, such as glioblastoma in the brain, are particularly reliant on crosstalk with their tumor microenvironment (TME) to satisfy their high energetic needs. To study the intricacies of this metabolic interplay, we interrogated the heterogeneity of the glioblastoma TME using single-cell and multi-omics analyses and identified metabolically rewired tumor-associated macrophage (TAM) subpopulations with pro-tumorigenic properties. These TAM subsets, termed lipid-laden macrophages (LLMs) to reflect their cholesterol accumulation, are epigenetically rewired, display immunosuppressive features, and are enriched in the aggressive mesenchymal glioblastoma subtype. Engulfment of cholesterol-rich myelin debris endows subsets of TAMs to acquire an LLM phenotype. Subsequently, LLMs directly transfer myelin-derived lipids to cancer cells in an LXR/Abca1-dependent manner, thereby fueling the heightened metabolic demands of mesenchymal glioblastoma. Our work provides an in-depth understanding of the immune-metabolic interplay during glioblastoma progression, thereby laying a framework to unveil targetable metabolic vulnerabilities in glioblastoma.


Related Papers